Zydus partners with Formycon for Keytruda biosimilar in US and Canada

Marquee JV announcedStrategic Transactions View source PDF Explain this filing

ZYDUSLIFE · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+0.0%Reaction day

₹920.00

prior close

₹926.80

announcement price

After-mkt

timing

Nifty 100market · index membership as recorded later (tracked since Jun 2026)-0.3%+0.3% vs market

Pharmaceuticals peers, median of 155sector-0.2%+0.2% vs sector

On the reaction day the stock moved 0.3 pts more than Nifty 100 and 0.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.0

10m

+0.1

15m

+0.5

30m

+0.4

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+0.0-0.3+0.3-0.2+0.2

Next day

+0.5+0.2+0.3+0.3+0.2

+0.8+0.9-0.1+0.6+0.2

+0.3+0.8-0.5+0.8-0.4

-0.8+0.2-1.0+0.1-0.9

-0.1+0.0-0.1-0.6+0.5

+0.0+0.6-0.6+0.2-0.2

15d

-0.5+1.5-1.9+0.2-0.6

-2.5+0.1-2.6-1.6-0.9

-3.6+0.8-4.4-2.6-1.0

+0.6-5.2+5.9-7.8+8.5

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 155Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Zydus Lifesciences, through its UAE subsidiary, has entered an exclusive licensing and supply partnership with Germany-based Formycon AG for FYB206, a biosimilar of Merck's blockbuster cancer drug Keytruda (Pembrolizumab), in the US and Canada. Formycon will develop, manufacture and supply the product while Zydus will handle commercialization. A BLA filing with USFDA is expected soon. The deal marks Zydus' entry into the North American biosimilar market and complements its proposed acquisition of Agenus Inc.'s US manufacturing facilities.

Likely market impact

Positive - entry into the high-value North American biosimilar oncology market, boosting future revenue potential.